271-73-8

Basic information

• Product Name: 1H-PYRAZOLO[3,4-B]PYRIDINE
• Synonyms: 1H-PYRAZOLO[3,4-B]PYRIDINE;1H-PYRAZO[3,4-B]PYRIDINE;1H-Pyrazolo[3,4-b]pyridine ,97%;7-Azaindazole;1H-pyrazolo[3,4-b]pyridine(SALTDATA: FREE);7-Aza-1H-indazole;Pyrazolo[3,4-b]pyridine
• CAS NO: 271-73-8
• Molecular Formula: C₆H₅N₃
• Molecular Weight: 119.12
• Product Categories: Heterocycles;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;Heterocycle-Pyridine series
• Mol File: 271-73-8.mol
• Article Data: 17

Chemical Properties

• Melting Point: 99-101°C
• Boiling Point: 120°C/0.1mmHg(lit.)
• Flash Point: 145.716 °C
• Appearance: /Solid
• Density: 1.349 g/cm³
• Vapor Pressure: 0.003mmHg at 25°C
• Refractive Index: 1.715
• Storage Temp.: Refrigerator, Under Inert Atmosphere
• Solubility: Chloroform, Ethyl Acetate
• PKA: 5.92±0.20(Predicted)
• CAS DataBase Reference: 1H-PYRAZOLO[3,4-B]PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-PYRAZOLO[3,4-B]PYRIDINE(271-73-8)
• EPA Substance Registry System: 1H-PYRAZOLO[3,4-B]PYRIDINE(271-73-8)

Safety Data

• Hazard Codes: Xn
• Statements: 22-20/21/22
• Safety Statements: 36/37
• TSCA: No
• Hazardous Substances Data: 271-73-8(Hazardous Substances Data)

Usage

Chemical Properties

Pale Orange Solid

Uses

A pyrazole derivative as kinase inhibitors.

Synthesis Reference(s)

Journal of Heterocyclic Chemistry, 7, p. 247, 1970 DOI: 10.1002/jhet.5570070146

InChI:InChI=1/C6H5N3/c1-2-5-4-8-9-6(5)7-3-1/h1-4H,(H,7,8,9)

Upstream product

• 63682-42-8 3-Diazapyrazolo<3,4-b>pyridine 
• 128071-75-0 2-bromopyridine-3-carboxaldehyde 
• 109-09-1 2-chloropyridine 
• 63682-46-2 C₆H₄N₅⁽¹⁺⁾*BF₄^(1-) 
• 6602-54-6 2-chloro-3-pyridinecarbonitrile 
• 36404-90-7 2-fluoropyridine-3-carboxaldehyde 
• 6752-16-5 1H-pyrazolo[3,4-b]pyridin-3-amine 
• 36404-88-3 2-chloro-3-carbaldehydepyridine 
• 75427-15-5 1-benzyl-1H-pyrazolo<3,4-b>pyridine 7-oxide 
• 75427-09-7 1-ethyl-1H-pyrazolo<3,4-b>pyridine 
• 75427-06-4 1‐benzyl‐1H‐pyrazolo[3,4‐b]pyridine 

Downstream Products

• 117007-52-0 3-iodo-1H-pyrazolo[3,4-b]pyridine 
• 1319591-26-8 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-trityl-pyrazolo[3,4-b]pyridine 
• 1383446-20-5 N-((1R,3S)-3-((5-fluoro-2-(1-trityl-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-4-yl)amino)cyclohexyl)-1-methyl-1H-imidazole-4-carboxamide 
• 1383447-03-7 N-((1R,3S)-3-((5-fluoro-2-(1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-4-yl)amino)cyclohexyl)-1-methyl-1H-imidazole-4-carboxamide 
• 1383446-28-3 3-bromo-1-trityl-pyrazolo[3,4-b]pyridine 
• 1470408-08-2 3-(1-morpholinopropyl-1H-indol-3-yl)-4-(1-(3-morpholinopropyl)-1H-pyrazolo[3,4-b]pyridine-3-yl)-1-phenyl-1H-pyrrole-2,5-dione 
• 1470408-07-1 3-(1-allyl-1H-indol-3-yl)-4-(1-(3-morpholinopropyl)-1H-pyrazolo[3,4-b]pyridine-3-yl)-1-phenyl-1H-pyrrole-2,5-dione 
• 1470408-06-0 3-(1-benzyl-1H-indol-3-yl)-4-(1-(3-morpholinopropyl)-1H-pyrazolo[3,4-b]pyridine-3-yl)-1-phenyl-1H-pyrrole-2,5-dione 
• 1470408-05-9 3-(1-isopropyl-1H-indol-3-yl)-4-(1-(3-morpholinopropyl)-1H-pyrazolo[3,4-b]pyridine-3-yl)-1-phenyl-1H-pyrrole-2,5-dione 
• 1470408-03-7 3-(1-(3-morpholinopropyl)-1H-pyrazolo[3,4-b]pyridine-3-yl)-1-phenyl-3-(1-vinyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione 
• 1470408-02-6 3-(1-(2-bromoethyl)-1H-indol-3-yl)-4-(1-(3-morpholinopropyl)-1H-pyrazolo[3,4-b]pyridine-3-yl)-1-phenyl-1H-pyrrole-2,5-dione 
• 1470408-01-5 3-(1H-indol-3-yl)-4-(1-(3-morpholinopropyl)-1H-pyrazolo[3,4-b]pyridine-3-yl)-1-phenyl-1H-pyrrole-2,5-dione 
• 1470408-00-4 3-(1-(tert-butyloxycarbonyl)-1H-indol-3-yl)-1-phenyl-4-(1-(3-morpholinopropyl)-1H-pyrazolo[3,4-b]pyridine-3-yl)-1H-pyrrole-2,5-dione 
• 1470407-99-8 3-(1-(tert-butyloxycarbonyl)-1H-indol-3-yl)-1-phenyl-4-(1H-pyrazolo[3,4-b]pyridine-3-yl)-1H-pyrrole-2,5-dione 

Relevant articles and documents

New 1-hydroxy-1,1-bisphosphonates derived from 1H-Pyrazolo[3,4-b]pyridine: Synthesis and characterization

A number of 1H-pyrazolo[3,4-b]pyridine derivatives, starting from 2-chloro-3-formyl pyridine, was synthesized to obtain new 1- hydroxybisphosphonates, a class of compounds with potential biological interest. Spectroscopic data were used to characterize all compounds and to identify N-1 and N-2 regioisomers, and mono- and bisphosphonates derivatives. X-ray diffractometry studies of compound 7a confirmed the proposed structure.

Novel Bisphosphonates Derived from 1H-Indazole, 1H-Pyrazolo[3,4-b]Pyridine, and 1H-Pyrazolo[3,4-b]Quinoline

Novel tetraethyl ethylene-1,1-bisphosphonate esters derived from 1H-indazole, 1H-pyrazolo[3,4-b]pyridine, and 1H-pyrazolo[3,4-b]quinoline were synthesized by a Michael addition reaction of tetraethyl ethylidene-1,1-bisphosphonate with the corresponding heterocycle, using conventional heating and microwave-assisted methods. The microwave-assisted method provides shorter reaction times and better yields. The hydrolysis of bisphosphonates afforded the corresponding bisphosphonic acids or salt, using concentrated hydrochloric acid or TMSBr/collidine, respectively. All new compounds were fully characterized, and their structures were assigned using 1H, 31P, and 13C NMR and IR spectroscopies and mass spectrometry. The molecular structure of compound 6 was confirmed by X-ray diffraction studies.

INHIBITORS OF CYCLIN DEPENDNT KINASE 7 (CDK7)

The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

PYRIMIDINE AND TRIAZINE DERIVATIVES AND THEIR USE AS AXL INHIBITORS

Compounds of the general formula(I): (I) processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.